Last mentioned: Mar 16, 2026
Rollout Milestone
Acoziborole enters the final stages of regulatory rollout for endemic regions.
Acoziborole Rollout
The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies.
Trial Results
Phase 2/3 clinical trial results for Acoziborole show high efficacy.
Fexinidazole Approval
First all-oral 10-day treatment for sleeping sickness is approved.
Fexinidazole Approval
The first all-oral treatment is approved, requiring 10 days of pills taken with food.
Research Begins
DNDi starts screening compounds for a single-dose HAT treatment.
NECT Launch
Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
Melarsoprol Introduced
Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.
The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.